- Prostate Cancer
- Urologic Oncology
- Prostate-Specific Antigen (PSA)
- Artificial Intelligence (AI)
- Active Surveillance
- Prostate Biopsy
- Biomarkers
We have relied on PSA for decades, but what’s next in precision screening for prostate cancer? In this episode of BackTable Urology, Dr. Jason Hafron from the Michigan Institute of Urology joins host Dr. Ruchika Talwar to discuss the evolving role of biomarkers and artificial intelligence in prostate cancer screening.
This podcast is supported by
Timestamps
Resources
- Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial
- Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA
- Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study
More about this episode
Together, Dr. Hafron and Dr. Talwar examine the ongoing challenges of PSA testing and the promise of next-generation blood-based biomarkers, including 4Kscore and IsoPSA tests. They explore how these advancements are reshaping detection, diagnosis, and risk stratification. The episode also highlights how these tools may improve active surveillance protocols, reduce unnecessary biopsies, and better personalize prostate cancer management for better outcomes.